- Date 12 Oct 2020
IQVIA, in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of how people in the community are affected by exposure to the coronavirus. IQVIA’s research will show what symptoms individuals experience, the length and severity and whether any medications or vitamin supplements they are taking affect the severity of their coronavirus symptoms.
The CARE Project is open to U.S. based residents who think they may have been exposed to the coronavirus, regardless of whether they have been diagnosed with COVID-19, including people who have continued with everyday life and may have been exposed. The project was established to advance understanding of COVID-19 as experienced in community settings.
The registry was launched in April 2020 and can be accessed at www.helpstopcovid19.com. Over three months, registrants are periodically asked to provide information via the internet to create a clearer picture about how people are responding to infection with COVID-19. Individual responses are kept confidential but are pooled with those from other participants to provide a solid body of data for learning about how COVID affects most people. More than 20,000 people have enrolled so far, representing all 50 states and Washington, D.C.
Nancy Dreyer, IQVIA’s chief scientific officer for Real World Solutions, said that, “While there has been so much focus on treatments for hospitalized cases of COVID-19, little is known about the symptoms experienced by most people in the community and what factors, if any, explain why some people do not get seriously ill. This project allows us to look at the possible roles of both prescription and nonprescription drugs, as well as nutraceuticals, such as vitamin D, zinc and herbals.”